Healthcare technology company Medtronic (NYSE: MDT) announced on Wednesday that it has received US Food and Drug Administration clearance for its LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system, expanding the instruments available to US surgeons.
Medtronic said the instrument combines robotic surgery with Medtronic's vessel-sealing technology, which has been used in more than 45 million procedures across more than 65 countries. Designed for use with the Valleylab FT10 energy platform, it seals and cuts vessels, thick tissue and lymphatics up to 7mm in diameter.
The Hugo RAS system is currently cleared for urologic procedures in the US, with Medtronic progressing plans to expand its indications to general and gynecologic surgery. The LigaSure RAS Maryland instrument was introduced on the Hugo system in Europe in 2025 following CE Mark approval.
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Insmed's ARIKAYCE sNDA granted priority review by FDA
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system